Maintenance fees coming due
8 maintenance fees come due in the 12 months from Nov 21, 2026, the next on Dec 11, 2026. Unpaid by Jun 11, 2027, that one lapses early.
A maintenance fee does not end a patent on its due date. It falls due at 3.5, 7.5
and 11.5 years from grant, and the patent lapses only if the fee is still unpaid at the end of the
six month grace period that follows.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Fee due | Lapses if unpaid | Expires | Confidence |
|---|---|---|---|---|---|---|---|
| US 10,316,038 | Pyrrolopyrimidine Itk Inhibitors for Treating Inflammation and Cancer In force Fee due Dec 11, 2026 Lapses if unpaid Jun 11, 2027 · High confidence | Aclaris Therapeutics, Inc. | In force | Dec 11, 2026 | Jun 11, 2027 | High confidence | |
| US 9,056,110 | Substituted Pyrimidinone-Phenyl-Pyrimidinyl Compounds In force Fee due Dec 16, 2026 Lapses if unpaid Jun 16, 2027 · High confidence | Aclaris Therapeutics, Inc. | In force | Dec 16, 2026 | Jun 16, 2027 | High confidence | |
| US 9,115,089 | Methyl/Fluoro-Pyridinyl-Methoxy Substituted Pyridinone-Pyridinyl Compounds and Fluoro-Pyrimidinyl-Methoxy Substituted Pyridinone-Pyridinyl Compounds In force Fee due Feb 25, 2027 Lapses if unpaid Aug 25, 2027 · High confidence | Aclaris Therapeutics, Inc. | In force | Feb 25, 2027 | Aug 25, 2027 | High confidence | |
| US 11,739,086 | Substituted Pyrrolopyridine Jak Inhibitors and Methods of Making and Using the Same In force Fee due Feb 28, 2027 Lapses if unpaid Aug 30, 2027 · High confidence | Aclaris Therapeutics, Inc. | In force | Feb 28, 2027 | Aug 30, 2027 | High confidence | |
| US 11,767,309 | Methods of Synthesizing Substituted Pyridinone-Pyridinyl Compounds In force Fee due Mar 26, 2027 Lapses if unpaid Sep 27, 2027 · High confidence | Aclaris Therapeutics, Inc. | In force | Mar 26, 2027 | Sep 27, 2027 | High confidence | |
| US 9,145,393 | Arylpyridinone Itk Inhibitors for Treating Inflammation and Cancer In force Fee due Mar 29, 2027 Lapses if unpaid Sep 29, 2027 · High confidence | Aclaris Therapeutics, Inc. | In force | Mar 29, 2027 | Sep 29, 2027 | High confidence | |
| US 11,820,775 | Pyrrolopyrimidine Itk Inhibitors In force Fee due May 21, 2027 Lapses if unpaid Nov 22, 2027 · High confidence | Aclaris Therapeutics, Inc. | In force | May 21, 2027 | Nov 22, 2027 | High confidence | |
| US 11,844,801 | Oral Compositions of MK2 Pathway Inhibitor for Treatment of Immune Conditions In force Fee due Jun 19, 2027 Lapses if unpaid Dec 20, 2027 · High confidence | Aclaris Therapeutics, Inc. | In force | Jun 19, 2027 | Dec 20, 2027 | High confidence |
8 of 8 patents shown. Soonest fee due date first, then patent number.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.